Tvardi Therapeutics, Inc. (TVRD) — Financial statements
Income statement, balance sheet, and cash flow for Tvardi Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 7↓66.0% | 21↓49.9% | 42↑81.8% | 23 | |
| Cost of Revenue | 0.10↓88.3% | 0.81↓87.4% | 6↓14.4% | 8↑383.5% | 2 | |
| Gross Profit | -0.10↓101.5% | 6↓56.5% | 15↓57.7% | 34↑60.0% | 21 | |
| Operating Expenses | ||||||
| R&D Expenses | 18↓45.0% | 33↓69.8% | 108↑18.1% | 92↑11.1% | 83 | |
| General & Administrative Expenses | 9 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 9↓66.9% | 26↓4.6% | 28↓8.2% | 30↑7.7% | 28 | |
| Other Expenses | 0.00↓100.0% | 3 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 27↓56.9% | 62↓54.3% | 136↑11.6% | 122↑10.2% | 111 | |
| Total Costs & Expenses | 27↓57.5% | 63↓55.8% | 142↑10.1% | 129↑15.4% | 112 | |
| Operating Results | ||||||
| Operating Income | -27↑52.0% | -56↑54.1% | -121↓38.8% | -88↑1.7% | -89 | |
| Depreciation & Amortization | 0.10↓50.5% | 0.19↓25.9% | 0.26↓84.5% | 2↑7.5% | 2 | |
| EBITDA | -27↑57.4% | -63↑46.8% | -118↓40.4% | -84↑3.5% | -87 | |
| EBIT | -27↑57.4% | -63↑46.7% | -118↓37.9% | -85↑3.4% | -88 | |
| Interest & Other Income | ||||||
| Net Interest Income | 1↑124.4% | -6↓528.3% | 1↑102.5% | 0.65↑8.0% | 0.60 | |
| Interest Income | 1↓51.4% | 3↑114.6% | 1↑101.5% | 0.65↑8.5% | 0.60 | |
| Interest Expense | 0.00↓100.0% | 8 | 0.00↓100.0% | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↓100.0% | 7↑295.5% | -4↓74.0% | -2↓221.0% | -0.64 | |
| Other Income / Expenses | 9↑155.1% | -15↓619.2% | 3↑44.7% | 2↑221.0% | 0.64 | |
| Income Before Tax | -18↑74.4% | -71↑39.9% | -119↓38.7% | -85↑3.4% | -88 | |
| Income Tax Expense | 0.00↑100.0% | -0.40 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -18↑74.3% | -71↑40.2% | -119↓38.7% | -85↑3.4% | -88 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -18↑74.3% | -71↑40.2% | -119↓38.7% | -85↑3.4% | -88 | |
| Bottom-Line Net Income | -25↑64.2% | -71↑40.2% | -119↓38.7% | -85↑3.4% | -88 | |
| EPS (Basic) | -2.46↑94.7% | -46.59↓2418.4% | -1.85↑15.9% | -2.20↑96.5% | -62.77 | |
| EPS (Diluted) | -3.26↑93.0% | -46.59↓2418.4% | -1.85↑15.9% | -2.20↑96.5% | -62.77 | |
| Weighted Average Shares | 7↑387.8% | 2↓83.7% | 9↑0.0% | 9↑564.1% | 1 | |
| Weighted Average Diluted Shares | 8↑411.7% | 2↓83.7% | 9↑0.0% | 9↑564.1% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.